⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for BIBW 2992 (Afatinib) and Vinorelbine

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: BIBW 2992 (Afatinib) and Vinorelbine

Official Title: Single-arm, Open-label, Multicentre Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) in Combination With Vinorelbine for the Treatment of Patients With Metastatic Breast Cancer With Intermediate HER2 Expression (HER2 2+ by Immunohistochemistry, Fluorescence In-situ Hybridisation (FISH) Negative) After Failure of First-line Therapy in the Metastatic Setting and Having Been Pre-treated With Anthracyclines

Study ID: NCT01531764

Study Description

Brief Summary: This open-label, single-arm, multicentre phase II trial will be performed in patients with intermediate HER2-positive, metastatic breast cancer (MBC)pretreated with anthracyclines and one first-line therapy in the metastatic setting. The main objective of the trial is to evaluate the efficacy and safety of BIBW 2992 in combination with vinorelbine in patients with intermediate HER2-positive MBC. If this trial shows promising results, further studies to evaluate the benefit of BIBW 2992 in combination with chemotherapy in this subgroup of intermediate HER2-positive patients with MBC are warranted. Patients will be followed until progression. After progression, for the purpose of analysing overall survival, information on vital status and subsequent treatment will be collected. The primary objective is to determine the 6-month progression free survival rate of BIBW 2992 and vinorelbine i.v. in patients with metastatic, HER2 IHC 2+, HER2 FISH-negative breast cancer. BIBW 2992 in combination with vinorelbine will provide a suitable combination to test the hypothesis that patients with metastatic breast cancer whose tumours are HER2 2+ by immunohistochemistry, but negative by fluorescence in-situ hybridisation (FISH) will benefit from a combination of a cytotoxic agent, i.e. vinorelbine, plus the dual irreversible EGFR/HER2-tyrosine kinase inhibitor BIBW 2992.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Klinikum St. Marien Amberg, Amberg, Bayern, Germany

Hämato-Onkologische Schwerpunktpraxis, München, Bayern, Germany

Caritas-Krankenhaus, Onkologisches Zentrum Regensburg, Regenburg, Bayern, Germany

Gynäkologische Praxis, Hildesheim, Niedersachsen, Germany

Schwerpunktpraxis für Hämatologie und Onkologie, Bottrop, Nordrhein-Westfalen, Germany

Universitätsklinikum Frauenklinik Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany

Otto-von-Guericke-Universität Frauenklinik Magdeburg, Magdeburg, Sachsen-Anhalt, Germany

Klinikum Chemnitz gGmbH, Chemnitz, Sachsen, Germany

Praxisklinik Krebsheilkunde für Frauen / Brustzentrum, Berlin, , Germany

Onkologisches Zentrum Süd, Vivantes Tumorzentrum, Berlin, , Germany

Internistische Praxisgemeinschaft Eppendorf, Hamburg, , Germany

OncoResearch Lerchenfled UG, Hamburg, , Germany

Contact Details

Name: Joachim Bischoff, MD

Affiliation: Otto-von-Guericke-Universität Magdeburg, Germany

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: